Global diversity and evolution of Salmonella enterica serovar Panama: a genomic epidemiology study
- PMID: 40720975
- DOI: 10.1016/j.lanmic.2025.101150
Global diversity and evolution of Salmonella enterica serovar Panama: a genomic epidemiology study
Abstract
Background: Non-typhoidal Salmonella is a globally important bacterial pathogen, typically associated with foodborne gastrointestinal infection. Some non-typhoidal Salmonella serovars can also colonise typically sterile sites in people to cause invasive non-typhoidal Salmonella disease. Salmonella enterica serovar Panama is responsible for a substantial number of cases of human bloodstream infection, but despite its global dissemination, numerous outbreaks, and a reported association with invasive non-typhoidal Salmonella disease, S enterica serovar Panama (S Panama) is understudied. We aimed to describe the genomic epidemiology and evolutionary history of S Panama to provide a vital baseline of understanding for this globally important serovar.
Methods: In this genomic epidemiology study, we analysed S Panama genomes derived from historical collections, national surveillance datasets, and publicly available epidemiological and whole-genome sequencing data which span the years 1931-2019. Maximum likelihood and Bayesian phylodynamic approaches were used to investigate population structure and evolutionary history and to infer geotemporal dissemination. A combination of different bioinformatic approaches with short-read and long-read data were used to characterise geographical and clade-specific trends in antimicrobial resistance (AMR) and genetic markers for invasiveness.
Findings: We analysed 836 S Panama genomes, of which 559 (67%) were sequenced as part of this study. The collection represents all inhabited continents and includes isolates collected between 1931 and 2019. We identified the presence of four geographically linked S Panama clades (C1 [ie, the Latin America and the Caribbean clade; n=338], C2 [ie, the European clade; n=124], C3 [ie, the Martinique clade; n=131], and C4 [ie, the Asia and Oceania clade; n=104]) and regional trends in AMR profiles. Most isolates (715 [86%] of 836) were pan-susceptible to antibiotics and belonged to clades circulating in Latin America and the Caribbean (64%, n=458). Most antibiotic-resistant isolates in our collection (113 [93%] of 121) fell within clades C4 (ie, the Asia and Oceania clade) and C2 (ie, the European clade), the latter of which had the highest invasiveness index values based on the conservation of 196 extraintestinal predictor genes.
Interpretation: This first large-scale phylogenetic analysis of S Panama has revealed important information about the population structure, AMR, global ecology, and genetic markers of invasiveness of the identified genomic subtypes. Our findings provide an important baseline for understanding S Panama infection. The presence of multidrug-resistant clades with elevated invasiveness index values should be monitored through ongoing surveillance, as such clades could pose an increased public health risk.
Funding: UK Research and Innovation Global Challenges Research Fund and Biotechnology and Biological Sciences Research Council, UK Medical Research Council, Wellcome Trust, John Lennon Memorial Scholarship, Institut Pasteur, Santé publique France, Fondation Le Roch-Les Mousquetaires, Investissement d'Avenir Programme, and Australian National Health and Medical Research Council.
Copyright © 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests DJI declares grants from the Australian National Health and Medical Research Council. EVR declares employment with the UK Health Security Agency. CVP declares a John Lennon memorial scholarship. BMP-S declares travel expenses to the Variable Viruses workshop (Dublin, Ireland, 2023). JCDH declares funding from the Wellcome Trust. For the purposes of open access, the authors have applied a CC BY public copyright license to any author-accepted manuscript version arising from this submission. KSB declares funding from the UK Medical Research Council, Biotechnology and Biological Sciences Research Council, and the Gates Foundation; consulting fees from RAND Europe; travel support for supporting conference attendance from the Academy of Medical Sciences, University of Zurich, and McGill University; membership of several scientific advisory boards; and co-directorship of the TARGET AMR research network.